TipRanks on MSN
Cocrystal Pharma reports Q3 EPS (19c) vs (49c) last year
We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988, our oral ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds ...
Norovirus triggers symptoms such as vomiting and diarrhoea. While it can be extremely unpleasant, it typically resolves ...
Finally! A microbiologist settles the debate on whether you need to keep the toilet lid down when you're not on the pot.
Louisville Metro Health and Wellness report public health researchers have detected an increase in norovirus levels in ...
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
Outbreaks of norovirus, an extremely contagious stomach bug, can spread quickly. “‘Tis the season for germs,” said Dr.
From symptoms and recovery tips to the truth about common myths, here’s everything you need to know about norovirus this ...
A norovirus outbreak on the Oceania Insignia cruise ship has sickened more than 70 people, the Centers for Disease Control and Prevention (CDC) has reported. According to a Tuesday, Oct. 21, release ...
Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results